Dr. István Hodász, CEO of Egis Pharmaceuticals PLC, emphasized that the pharmaceutical industry is already a key sector in Hungary, and it will stay that way in the coming decades, as well. It has been agreed that Egis will set up an onsite department of university faculty at its sites so that the students can attend university classes, professional training and interactive plant visits in a real, industrial environment and in the unique, scientific and technological training centre of Egis.
It is a cardinal point to create an appropriate educational environment for promoting talents and innovative ideas so that future pharmacists and doctors will be able to join the international competition and, after graduation, they contribute added value with their work to the development of the health industry.
The latter idea will be promoted by the Hőgyes-Schöpf-Merei Pharmaceutical Research Centre - to be built under the Semmelweis XXI Development project - which will provide the Semmelweis University with the opportunity to become one of the top 100 universities of the world. It is also important for Egis that future pharmacists receive training that is adapted to the quickly changing industrial environment. To that end, as was announced upon signing the agreement, the company advised the management of the Faculty of Pharmacy already in the initial planning phase about the quality assurance requirements that the new Pharmaceutical Research Centre has to fulfill with regard to pharmaceutical production and research.
Egis has gained century-long experience in pharmaceutical development and in the international marketing of medicines. Dr. István Hodász added that Egis Pharmaceuticals also shares this knowledge with the university so that its proven wide experience and extensive market skills help the university to put its product development concepts into practice.
More details can be read in our press release.